Royal Philips Enrolls First Patient in Trial for New Peripheral Artery Disease Catheter

MT Newswires Live11-05 00:43

Royal Philips (PHG) said Monday it enrolled the first patient in a clinical trial, studying a new catheter that combines laser atherectomy and intravascular lithotripsy for treating peripheral artery disease.

The Cardiovascular Institute of the South in Louisiana successfully treated a 78-year-old man with peripheral vascular disease using the new Philips laser catheter, the company said.

The trial aims to enroll up to 155 patients at 30 US sites.

The study's primary endpoints are freedom from major adverse events within 30 days and achieving 50% or less residual stenosis after the procedure, with a 12-month patient follow-up, the company said.

Shares of Royal Philips were up 2.6% in recent trading.

Price: 27.19, Change: +0.70, Percent Change: +2.62

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2481369435?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-05 00:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2481369435","market":"sg","top_or_hot":-1,"title":"Royal Philips Enrolls First Patient in Trial for New Peripheral Artery Disease Catheter","media":"MT Newswires Live","content":"<html><body><p> Royal Philips (PHG) said Monday it enrolled the first patient in a clinical trial, studying a new catheter that combines laser atherectomy and intravascular lithotripsy for treating peripheral artery disease.</p><p>The Cardiovascular Institute of the South in Louisiana successfully treated a 78-year-old man with peripheral vascular disease using the new Philips laser catheter, the company said.</p><p>The trial aims to enroll up to 155 patients at 30 US sites.</p><p>The study's primary endpoints are freedom from major adverse events within 30 days and achieving 50% or less residual stenosis after the procedure, with a 12-month patient follow-up, the company said.</p><p>Shares of Royal Philips were up 2.6% in recent trading.</p><p>Price: 27.19, Change: +0.70, Percent Change: +2.62</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Royal Philips Enrolls First Patient in Trial for New Peripheral Artery Disease Catheter</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRoyal Philips Enrolls First Patient in Trial for New Peripheral Artery Disease Catheter\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-05 00:43 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Royal Philips (PHG) said Monday it enrolled the first patient in a clinical trial, studying a new catheter that combines laser atherectomy and intravascular lithotripsy for treating peripheral artery ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4082","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2481369435","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481369435","pubTimestamp":1730738617,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Royal Philips  said Monday it enrolled the first patient in a clinical trial, studying a new catheter that combines laser atherectomy and intravascular lithotripsy for treating peripheral artery disease.The Cardiovascular Institute of the South in Louisiana successfully treated a 78-year-old man with peripheral vascular disease using the new Philips laser catheter, the company said.The trial aims to enroll up to 155 patients at 30 US sites.The study's primary endpoints are freedom from major adverse events within 30 days and achieving 50% or less residual stenosis after the procedure, with a 12-month patient follow-up, the company said.Shares of Royal Philips were up 2.6% in recent trading.Price: 27.19, Change: +0.70, Percent Change: +2.62","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4082":"医疗保健设备","BK4017":"黄金","BK4585":"ETF&股票定投概念","BK4588":"碎股","RGLD":"皇家黄金","LU0345780521.USD":"NINETY ONE GSF GLOBAL GOLD \"A\" (USD) INC","LU0345780281.USD":"NINETY ONE GSF GLOBAL GOLD \"A\"  ACC","PHG":"飞利浦"},"translate_title":"皇家飞利浦招募首例患者参加新型外周动脉疾病导管试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RGLD":1,"PHG":0.9},"content_text":"Royal Philips (PHG) said Monday it enrolled the first patient in a clinical trial, studying a new catheter that combines laser atherectomy and intravascular lithotripsy for treating peripheral artery disease.The Cardiovascular Institute of the South in Louisiana successfully treated a 78-year-old man with peripheral vascular disease using the new Philips laser catheter, the company said.The trial aims to enroll up to 155 patients at 30 US sites.The study's primary endpoints are freedom from major adverse events within 30 days and achieving 50% or less residual stenosis after the procedure, with a 12-month patient follow-up, the company said.Shares of Royal Philips were up 2.6% in recent trading.Price: 27.19, Change: +0.70, Percent Change: +2.62","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2481369435"}